RecruitingNCT06227728
Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.
Analysis of PD-L1, TMB, CTDNA in Immunotherapy Response Monitoring and Prediction in Advancer Lung Cancer Treatment.
Sponsor
Gene Solutions
Enrollment
50 participants
Start Date
Mar 22, 2024
Study Type
OBSERVATIONAL
Summary
This is an observational clinical trial, aiming to investigate whether the ctDNA dynamics could predict early response to ICIs in patients with advanced-stage cancer. Moreover, conventional tumor markers PD-L1, TMB and MSI are to be investigated for their combined prognostic values in ICI treatment.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria5
- years and older, both genders.
- Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric…) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed.
- FFPE/FNA sample is available.
- Compliant with treatment protocol.
- Patients consented to participate in the study.
Exclusion Criteria5
- Patients already started ICI before enrollment.
- Consolidation ICI (eg. Durvalumab).
- Patients already started chemotherapy before enrollment.
- Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.
- Patients did not agree to participate in the studies.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06227728